Health Economics›Breast cancer›Adjuvant therapy

Adjuvant therapy

Breast cancer · 74 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
TCHP (Docetaxel) Variant #01	ERBB2	R 81 743	21d	—	—	6	R 203 970 PFS proxy	1
Trastuzumab emtansine monotherapy Variant #01	ERBB2	R 41 405	21d	—	—	4	R 165 620 PFS proxy	1
TCH (Docetaxel) Variant #01	ERBB2	R 36 089	21d	—	—	12	R 160 300 PFS proxy	2
TCyH (Docetaxel) Variant #01	ERBB2	R 35 226	21d	—	—	~13	~R 126 847 indirect	—
Docetaxel and Trastuzumab (TH) Variant #02	ERBB2	R 31 039	21d	~12.4 mo	~26.5 mo	~6	~R 101 881 PFS proxy · indirect	11
Pertuzumab and Trastuzumab hyaluronidase monotherapy Variant #01	ERBB2	R 26 380	21d	—	—	~14	~R 369 315 indirect	—
Olaparib monotherapy Variant #01	BRCA	R 19 741	28d	—	—	2	R 39 483 PFS proxy	1
Neratinib monotherapy Variant #02	ERBB2	R 19 339	28d	—	—	52	R 1 005 645 PFS proxy	1
Abemaciclib and ET Variant #01 Partial	ER	R 15 920	28d	—	—	~130	~R 413 912 indirect	—
Lapatinib and Trastuzumab Variant #04	ERBB2	R 15 652	42d	~2.6 mo	~14.0 mo	~3	~R 32 897 PFS proxy · indirect	2
Paclitaxel and Trastuzumab (TH) Variant #01	ERBB2	R 15 366	21d	~12.9 mo	~24.0 mo	~4	~R 28 660 PFS proxy · indirect	10
CMF and H Variant #01	ERBB2	R 14 791	21d	—	—	~17	~R 93 433 indirect	—
Letrozole and Ribociclib Variant #01	ER	R 14 244	28d	~25.3 mo	~63.9 mo	~65	~R 565 168 PFS proxy · indirect	2
Anastrozole and Ribociclib Variant #01	ER	R 14 032	28d	—	—	~65	~R 551 403 indirect	—
Trastuzumab monotherapy Variant #09	ERBB2	R 9 373	42d	—	—	10	R 51 549 PFS proxy	2
FEC and H Variant #01	ERBB2	R 7 114	21d	—	—	~18	~R 91 635 indirect	—
CTCb Variant #01 Partial	—	R 6 855	—	—	—	1	R 6 855 PFS proxy	1
ddEC-ECT Variant #01 Partial	—	R 5 254	21d	—	—	~2	~R 10 508 indirect	—
FNC Variant #01	—	R 4 611	21d	—	—	~6	~R 27 667 indirect	—
FEC Variant #01	ERBB2	R 2 049	21d	—	—	2	R 4 097 PFS proxy	7
CEF/CMF Variant #01	—	R 2 021	21d	—	—	~12	~R 14 293 indirect	—
Cyclophosphamide monotherapy Variant #01	—	R 1 680	28d	—	~15.8 mo	~1	~R 1 680 PFS proxy · indirect	1
Toremifene monotherapy Variant #01	ER	R 1 481	28d	—	—	~65	~R 96 275 indirect	—
CAMFP Variant #01	—	R 1 133	21d	—	—	~4	~R 4 533 indirect	—
AVCF Variant #01	—	R 1 045	30d	—	—	~12	~R 12 537 indirect	—
PAF Variant #01	—	R 1 030	42d	—	—	~17	~R 9 387 indirect	—
Tamoxifen-Exemestane Variant #01	ER	R 1 022	28d	—	—	39	R 28 352 PFS proxy	1
CPB Variant #01 Partial	—	R 971	—	—	—	~1	~R 971 indirect	—
CMFPT Variant #01	—	R 949	28d	—	—	~12	~R 11 390 indirect	—
Fluorouracil and Methotrexate (MF) Variant #01	—	R 948	28d	—	—	~3	~R 2 369 indirect	—
CMFT Variant #01	ER	R 910	28d	—	—	~2	~R 1 819 indirect	—
FAC and BCG Variant #01 Partial	—	R 898	28d	—	—	~8	~R 5 153 indirect	—
Exemestane monotherapy Variant #01	ER	R 886	90d	~3.8 mo	~45.1 mo	~65	~R 57 558 PFS proxy · indirect	10
Cyclophosphamide and Doxorubicin (AC) Variant #01	—	R 864	21d	—	—	6	R 5 185 PFS proxy	1
CMFP Variant #01	—	R 813	28d	—	—	~12	~R 9 750 indirect	—
Paclitaxel monotherapy Variant #02	—	R 734	28d	~6.4 mo	~16.8 mo	~7	~R 5 141 PFS proxy · indirect	28
ACT Variant #01	—	R 713	28d	—	—	26	R 7 009 PFS proxy	2
ACT Variant #01	ER	R 713	28d	—	—	26	R 7 009 PFS proxy	2
PFT Variant #01	ER	R 558	42d	—	—	~43	~R 14 820 indirect	—
PFT Variant #01	—	R 558	42d	—	—	~43	~R 14 820 indirect	—
Letrozole-Tamoxifen Variant #01	ER	R 508	28d	—	—	~39	~R 14 972 indirect	—
Tamoxifen-Letrozole Variant #01	ER	R 508	28d	—	—	~39	~R 18 017 indirect	—
CFP Variant #01	—	R 500	42d	—	—	~10	~R 4 996 indirect	—
CFP and Bilateral oophorectomy Variant #01	ER	R 500	35d	—	—	~2	~R 999 indirect	—
CMFVP Variant #01	—	R 399	7d	—	—	~52	~R 13 207 indirect	—
TMF Variant #01 Partial	—	R 382	42d	—	—	~6	~R 2 290 indirect	—
Letrozole monotherapy Variant #01	ER	R 371	28d	~14.5 mo	~51.3 mo	~2	~R 742 PFS proxy · indirect	16
PF Variant #01	—	R 353	42d	—	—	~2	~R 707 indirect	—
Tamoxifen-Anastrozole Variant #01	ER	R 296	28d	—	—	39	R 9 758 PFS proxy	1
Anastrozole monotherapy Variant #01	ER	R 159	28d	~13.8 mo	~42.7 mo	~6	~R 955 PFS proxy · indirect	12
Anastrozole monotherapy Variant #01	ER\|ERBB2	R 159	28d	~13.8 mo	~42.7 mo	~6	~R 955 PFS proxy · indirect	12
PT Variant #01	—	R 145	28d	—	—	~13	~R 1 884 indirect	—
PT Variant #01	ER	R 145	28d	—	—	~13	~R 1 884 indirect	—
Tamoxifen monotherapy Variant #01	ER	R 137	28d	—	—	130	R 17 763 PFS proxy	3
Melphalan monotherapy Variant #01	—	R 73	42d	~50.0 mo	~22.2 mo	~18	~R 1 320 PFS proxy · indirect	7
Oophorectomy Partial	—	—	—	—	—	—	—	—
Observation Partial	ERBB2	—	—	—	—	—	—	1
Radiation therapy N/A - radiation	—	—	49d	~25.5 mo	~10.6 mo	—	—	24
Levamisole monotherapy Variant #01 Partial	—	—	14d	—	—	~2	—	—
Placebo Partial	ER	—	—	—	—	—	—	1
Placebo Partial	—	—	—	—	—	—	—	1
CFP and Oophorectomy Partial	—	—	—	—	—	—	—	—
CMFL Partial	—	—	—	—	—	—	—	—
Thiotepa monotherapy Variant #01 Partial	—	—	3d	—	—	~1	—	—
Observation Partial	TNBC	—	—	—	—	—	—	1
Aromatase inhibitor monotherapy Variant #01 Partial	ER	—	—	—	—	~1	—	—
AVCMF Partial	—	—	—	—	—	—	—	—
Observation Partial	—	—	—	—	—	—	—	1
Placebo Partial	TNBC	—	—	—	—	—	—	1
Placebo Partial	ERBB2	—	—	—	—	—	—	1
Bilateral Oophorectomy Partial	ER	—	—	—	—	—	—	—
Bilateral oophorectomy Partial	ER	—	—	—	—	—	—	—
Observation Partial	ER	—	—	—	—	—	—	1
Trastuzumab and hyaluronidase monotherapy Variant #01 Partial	ERBB2	—	21d	—	—	~18	—	—

74 of 74 regimens shown